Všechny fotografie(1)

Key Documents

COO/COA

View All Documentation

Y0001494

Hydrochlorothiazide for peak identification

Name: Hydrochlorothiazide for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyma:

Hydrochlorothiazide, 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen

Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):

C₇H₈ClN₃O₄S₂

Číslo CAS:

58-93-5

Molekulová hmotnost:

297.74

MDL number:

MFCD00051765

UNSPSC Code:

41116107

PubChem Substance ID:

329831457

NACRES:

NA.24

Doporučené produkty

Slide 1 of 10

1 of 10

H1200000

Hydrochlorothiazide

Y0001428

Pheniramine impurity A

Y0001709

Lisinopril for system suitability A

Sigma-Aldrich

H2766

Sodium 1-heptanesulfonate

Y0000605

Loratadine impurity H

USP

1163264

Dapagliflozin Related Compound A

N0200000

Naphazoline impurity A

Y0000849

Clotrimazole for peak identification

BP743

Enalapril diketopiperazine

Y0001635

Diclofenac for system suitability

grade

pharmaceutical primary standard

API family

hydrochlorothiazide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydrochlorothiazide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Carbonic anhydrase inhibitor

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu

Popis

Stanovení ceny

signalword

Warning

hcodes

H351

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Carc. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life.

Soham Rej et al.

Drugs & aging, 31(12), 911-916 (2014-10-22)

Little is known about how lithium should be dosed to achieve therapeutic but safe serum concentrations in older adults. In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. This was a cross-sectional analysis of 63

The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial.

Dragos Vinereanu et al.

American heart journal, 168(4), 446-456 (2014-09-30)

The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes. This is a prospective, randomized

Hydrochlorothiazide: is it a wise choice?

James J DiNicolantonio

Expert opinion on pharmacotherapy, 13(6), 807-814 (2012-03-20)

Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet

Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients.

Sverre E Kjeldsen et al.

Journal of clinical hypertension (Greenwich, Conn.), 15(6), 380-388 (2013-06-05)

Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations

Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?

Edgar V Lerma

Current hypertension reports, 13(5), 386-395 (2011-07-29)

Hypertension remains an important problem that increases the risk of cardiovascular disease and is a leading cause of mortality worldwide. Achieving long-term control of arterial hypertension, which has an estimated prevalence of 28% in the US adult population, would translate

Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.